CDK4/6 InhibitorThe CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Sponsor:

American Society of Clinical Oncology

Code:

NCT06377852

Conditions

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Not accepted

Interventions

Palbociclib 125mg

Ribociclib 600mg

Ribociclib

Palbociclib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by American Society of Clinical Oncology on 2026-06-29.